Abstract: A vehicle travel control apparatus is provided which includes: an automatic brake control part configured to perform an automatic brake control that automatically applies a brake force to a host vehicle when there is a probability of collision with an obstacle in front of the host vehicle; and a drive force recovery control part configured to increase, in response to an accelerator operation by a driver, a target drive force to a demand drive force from the driver by a predetermined increase amount per unit time after having performed the automatic brake control. The drive force recovery control part determines the predetermined increase amount per unit time such that the predetermined increase amount per unit time becomes greater as the brake force applied by the automatic brake control part during the automatic brake control is smaller.

Abstract: An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 ? or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative.

Abstract: In a roller member where a rotary shaft is inserted through a through-hole of a roller part so that the roller part is removably mounted on the rotary shaft, the rotary shaft is provided with a positioning retention part for retaining one end of the roller part. Further, the rotary shaft is provided with an engagement recess at place on its portion outward of the other end of the roller part. An engagement protrusion is provided at a snap fit portion extended axially outward from the other end of the roller part. In a state where the snap fit portion is elastically deformed in a direction opposite to the extension direction, the engagement protrusion is engaged with the engagement recess.

Abstract: In a roller member where a rotary shaft is inserted through a through-hole of a roller part so that the roller part is removably mounted on the rotary shaft, the rotary shaft is provided with a positioning retention part for retaining one end of the roller part. Further, the rotary shaft is provided with an engagement recess at place on its portion outward of the other end of the roller part. An engagement protrusion is provided at a snap fit portion extended axially outward from the other end of the roller part. In a state where the snap fit portion is elastically deformed in a direction opposite to the extension direction, the engagement protrusion is engaged with the engagement recess.

Abstract: An objective of the present invention is to provide methods of producing human collagen molecules that are easy to isolate and purify and that have a structure substantially equivalent to that of a natural collagen molecule, wherein host cells that are transduced with a collagen gene synthesize large amounts of human collagen protein derived from a gene introduced into a high exogenous gene expression vector. Another objective of the present invention is to provide collagen molecules produced by the production methods. The present inventors discovered that a large amount of human collagen hardly contaminated with host cell-derived collagen could be produced, by selecting from various mammalian cells a host cell that has low collagen expression and introducing a collagen gene construct into a vector capable of high exogenous gene expression.

Abstract: A conveyance device has a carriage drive for driving and propelling a pair of left and right carriage units which individually support left and right sides of an object to be conveyed. A pair of left and right screw shafts is pivotally supported in a rotatable manner along the movement path of the carriage units. Driven rollers are pivotally supported in a rotatable manner by the carriage units and engage with the screw shafts. A transmission connects the pair of left and right screw shafts through the outside of a conveyance path such that the left and right screw shafts are linked and coupled; and a single motor drives the pair of left and right screw shafts through the transmission means.

Abstract: An object of the present invention is to provide a pharmaceutical composition that improves intestinal absorption of a compound having a structure represented by the general formula [1]. The composition containing a compound represented by the general formula [1] or a salt thereof and (b) a lipophilic substance improves intestinal absorption of the compound. In the formula, A represents —(NR4)—, —(CR5R6)— or the like; B represents an alkylene group or an alkenylene group; R1 represents an alkyl group, an alkenyl group or the like; R2 represents an adamantylalkyl group or the like; R3 represents an unsaturated heterocyclic ring; R4, R5 and R6 each represent a hydrogen atom or the like; and X represents an oxygen atom or the like.

Abstract: An eye drop composition in which the degradation of isopropyl unoprostone in an eye drop is prevented by adding trometamol to the eye drop containing isopropyl unoprostone.

Abstract: An objective of the present invention is to provide methods of producing human collagen molecules that are easy to isolate and purify and that have a structure substantially equivalent to that of a natural collagen molecule, wherein host cells that are transduced with a collagen gene synthesize large amounts of human collagen protein derived from a gene introduced into a high exogenous gene expression vector. Another objective of the present invention is to provide collagen molecules produced by the production methods. The present inventors discovered that a large amount of human collagen hardly contaminated with host cell-derived collagen could be produced, by selecting from various mammalian cells a host cell that has low collagen expression and introducing a collagen gene construct into a vector capable of high exogenous gene expression.

Abstract: A clear ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V), 0.003 to 0.01% (W/V) benzalkonium chloride and at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. A method of preventing white turbidity in an ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V) and 0.003 to 0.01% (W/V) benzalkonium chloride, the method involving adding to the solution at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic.

Abstract: An object of the present invention is to provide better formulations of a latanoprost ophthalmic solution. The present invention provides a clear ophthalmic solution comprising latanoprost as an active ingredient and benzalkonium chloride as a preservative wherein white turbidity due to a change of formulation is prevented by at least one means selected from the following 1) to 3); 1) adding a surfactant, 2) using benzalkonium chloride represented by the formula of [C6H5CH2N(CH3)2R]Cl (wherein R is alkyl having 12 carbon atoms) as the preservative and 3) adding a nonionic tonicity agent as a tonicity agent.

Abstract: An eye drop composition in which the degradation of isopropyl unoprostone in an eye drop is prevented by adding trometamol to the eye drop containing isopropyl unoprostone.

Abstract: The present invention provides a method for preventing the degradation of a thermally unstable medicament in an eye drop containing the medicament thereby to stabilize the eye drop. By adding an organic amine to an eye drop containing a thermally unstable medicament, the degradation of the medicament in the eye drop can be effectively prevented, and therefore the eye drop can be stably stored.

Abstract: An object of the present invention is to provide a pharmaceutical composition that improves intestinal absorption of a compound having a structure represented by the general formula [1]. The composition containing a compound represented by the general formula [1] or a salt thereof and (b) a lipophilic substance improves intestinal absorption of the compound. In the formula, A represents —(NR4)—, —(CR5R6)— or the like; B represents an alkylene group or an alkenylene group; R1 represents an alkyl group, an alkenyl group or the like; R2 represents an adamantylalkyl group or the like; R3 represents an unsaturated heterocyclic ring; R4, R5 and R6 each represent a hydrogen atom or the like; and X represents an oxygen atom or the like.

Abstract: A method of stabilizing latanoprost in an ophthalmic solution containing 0.005% (W/V) of latanoprost to be stored to be stored at room temperature (i) by adding 0.1 to 2% (W/V) of ?-aminocaproic acid to the solution or (ii) by adding 0.1 to 2% (W/V) of ?-aminocaproic acid and adjusting the pH of the solution to 5.0 to 6.25.

Abstract: A clear ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V), 0.003 to 0.01% (W/V) benzalkonium chloride and at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. A method of preventing white turbidity in an ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V) and 0.003 to 0.01% (W/V) benzalkonium chloride, the method involving adding to the solution at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic.

Abstract: The present invention provides a method for preventing the degradation of a thermally unstable medicament in an eye drop containing the medicament thereby to stabilize the eye drop. By adding an organic amine to an eye drop containing a thermally unstable medicament, the degradation of the medicament in the eye drop can be effectively prevented, and therefore the eye drop can be stably stored.

Abstract: An object of the present invention is to enhance the efficacy of roflumilast in an eye drop containing roflumilast as an active ingredient. By formulating at least one type of viscosity-increasing agent in the eye drop containing roflumilast as an active ingredient, an eye drop in which the efficacy of roflumilast is enhanced can be prepared.

Abstract: An object of the present invention is to prevent the generation of chlorine dioxide in a liquid preparation for ophthalmic use containing a chlorite. A liquid preparation for ophthalmic use containing a preservative composition for ophthalmic use comprising a chlorite and at least one stabilizer selected from the following 1) to 7): 1) creatinine; 2) geraniol; 3) glucose; 4) tocopherol acetate; 5) oxyquinoline sulfate; 6) a sugar alcohol; and 7) a polyoxyethylene sorbitan fatty acid ester can prevent the generation of chlorine dioxide, and is therefore excellent in safety and exhibits a sustained preservative effect for a prolonged period of time.

Abstract: An object of the present invention is to provide a prostaglandin-containing product, wherein when an aqueous liquid preparation containing a prostaglandin derivative having at least a fluorine atom in its molecule as an active ingredient is stored in a resin container subjected to a sterilization treatment, a decrease in the content of the prostaglandin derivative in the aqueous liquid preparation can be inhibited. The aqueous liquid preparation containing the prostaglandin derivative having at least a fluorine atom in its molecule as an active ingredient is stored in the resin container subjected to a sterilization treatment with ethylene oxide gas. By doing this, a decrease in the content of the prostaglandin derivative in the aqueous liquid preparation can be inhibited.